Fibrinogen ␣C residues 242-424 have been shown to have a major regulatory role in the activation of factor XIII-A 2 B 2 (FXIII-A 2 B 2 ); however, the interactions underpinning this enhancing effect have not been determined. Here, we have characterized the binding of recombinant (r)FXIII-A subunit and FXIII-A 2 B 2 with fibrin(ogen) and fibrin ␣C residues 233-425. Using recombinant truncations of the fibrin ␣C region 233-425 and surface plasmon resonance, we found that activated rFXIII-A bound ␣C 233-425 (K d of 2.35 ؎ 0.09M) which was further localized to ␣C 389-403. Site-directed mutagenesis of this region highlighted Glu396 as a key residue for binding of activated rFXIII-A. The
Introduction
Fibrinogen is a 340 000-Da glycoprotein composed of 2 sets of disulphide linked nonidentical polypeptide chains; A␣, B␤, and ␥. 1, 2 Thrombin catalyzes the polymerization of fibrinogen to fibrin by sequentially cleaving fibrinopeptide A and fibrinopeptide B (FpB), initiating lateral aggregation of protofibrils and fiber formation. [3] [4] [5] Factor XIII (FXIII) is a 325.8-kDa heterotetramer composed of 2 identical globular A subunits noncovalently bound to 2 FXIII-B subunits. [6] [7] [8] FXIII-A 2 B 2 is converted to its active form by the thrombin catalyzed hydrolysis of the Arg37-Gly38 peptide bond at the N-terminal of the FXIII-A subunit. 9 In the presence of calcium, the thrombin-cleaved FXIII-A 2 B 2 complex dissociates, yielding FXIII-B 2 and activated FXIII-A 2 . [10] [11] [12] Calcium has been shown to cause small but significant conformational changes in FXIII-A during activation, exposing potential exosites within FXIII-A. [13] [14] [15] Activated FXIII-A 2 stabilizes the forming protofibril by introducing ⑀-amino(␥-Glutamyl)Lysine cross-links between carboxyl terminal portions of adjacent fibrin ␥ chains, before lateral association of the protofibril. 16 Cleavage of FpB and subsequent release of the ␣C regions from the central E region initiates lateral aggregation of protofibrils and enables activated FXIII-A 2 to cross-link adjacent ␣C, stabilizing the developing fiber and making it more resistant to fibrinolysis. 17, 18 Interactions between fibrin(ogen) and FXIII-A 2 B 2 are well documented; Greenberg and Shuman 19 demonstrated that nonactivated plasma FXIII-A 2 B 2 bound specifically to fibrinogen by the FXIII-A 2 subunits with an equilibrium constant (K d ) of 10nM. Greenberg et al 20 also noted that binding of FXIII-A 2 B 2 was unaffected by fibrinogen polymerization, suggesting that the interaction must occur before thrombin cleavage of fibrinopeptide A and FpB. Hornyak and Shafer 21 compared activated, nonactivated platelet FXIII-A and nonactivated plasma FXIII-A 2 B 2 for binding to fibrin clots (K d of 2.1M, 14M, and 200nM, respectively). In addition, Hornyak and Shafer examined the effect of fibrin on the activation of platelet FXIII-A, a phenomenon previously described by Credo et al. 22 , 23 Hornyak and Shafer found that fibrin did not promote activation of platelet FXIII-A alone, but it did enhance FXIII-A 2 B 2 activation, suggesting that this effect might be mediated by the dissociation of the B chains. 21 Immunoblotting of fibrinogen plasmin degradation products identified binding regions in the A␣ and B␤ chains for platelet FXIII-A. Binding was not observed on the fibrinogen ␥ chains. 24 Interestingly, Siebenlist et al suggested that plasma FXIII preferentially bound to fibrinogen molecules containing the variant ␥Ј because fibrinogen containing ␥A␥Ј copurified with the nonactivated FXIII-A 2 B 2 , and that this interaction takes place by the B subunit of FXIII. 25 The binding region on fibrin for placental FXIII-A was first localized by Procyk et al. 26 Procyk used several antibodies specific to various regions of fibrinogen [T2G1 (anti-B␤15-21), 1D4/x1-f (anti-A␣389-402), 4-2/x1-f (anti-␥392-406), Fd4-7B3 (anti-␥[Fragment D]), 1C2-2 (anti-A␣529-539)] to identify the key regions thought to be involved in FXIII-A binding. The results have shown that the antibodies against the B␤ chain and the C-terminal region of the ␥ chains [anti-B␤15-21, anti-␥392-406, and anti-␥(Fragment D)] did not appreciably affect the binding of activated FXIII-A. The binding was however substantially lowered by an anti-A␣389-402 antibody and furthermore by cyanogen bromide fragment Hi2-DSK (A␣241-476), suggesting that the location of the FXIII-A binding site was within ␣C region A␣389-402. In agreement with Hornyak and Shafer, 21 Procyk et al 26 showed that the activation of FXIII-A by thrombin in the presence of calcium was necessary to enable a binding interaction. This ␣C binding region is consistent with previous work by Credo et al, 23 in which ␣C residues 242-424 were found to enhance FXIII-A 2 B 2 activation. Therefore, it would seem reasonable to speculate that binding of activated FXIII-A or FXIII-A 2 B 2 or both would occur within this ␣C region.
The aim of the current study was to characterize the interactions between FXIII and the fibrin(ogen) ␣C region to better understand the role of the ␣C region in regulating FXIII activation. This was performed using recombinantly expressed truncations of the ␣C region ␣233-425 and investigating binding interactions with (1) nonactivated recombinant FXIII-A (rFXIII-A), (2) activated rFXIII-A, (3) nonactivated plasma FXIII-A 2 B 2 , and (4) thrombincleaved FXIII-A 2 B 2 in the presence and absence of calcium by surface plasmon resonance (SPR). In addition, site-directed mutagenesis of the ␣C binding region 389-402 has enabled us to identify for the first time a key amino acid residue involved in the binding of activated rFXIII-A. Furthermore we have confirmed (1) its specificity for activated rFXIII-A, (2) that the binding is specific for the calcium-induced conformational change observed during rFXIII-A activation, and (3) the binding is independent of rFXIII-A cross-linking activity. Finally, we have identified a novel high-affinity FXIII-A 2 B 2 binding site on the ␣C region of fibrinogen.
Methods

Development of glutathione-S-transferase ␣ fragments and FXIII-A expression constructs
Nine human fibrinogen ␣C fragments: ␣233-425, ␣233-403, ␣233-388, ␣233-375, ␣233-341, ␣233-290, ␣233-265, ␣289-425, and ␣371-425 (termed ␣ fragment 1-9, respectively) were recombinantly expressed in Escherichia coli with the use of pGEX-6P-1 glutathione-S-transferase (GST) gene fusion system (GE Healthcare). Variants of the ␣C region 371-425 (Pro389Ala, Asp390Ala, Trp391Ala, Gly392Ala, Phe394Ala, Glu396Ala, Gly399Ala, Ser402Ala) were produced by introducing site-directed point mutations of highly conserved residues with the use of the QuickChangeII Site Directed Mutagenesis Kit (Stratagene) carried out according to the manufacturers instructions. DNA sequencing confirmed the ␣C fragments and the mutations. See supplemental Data for further details (available on the Blood Web site; see the Supplemental Materials link at the top of the online article).
Full-length rFXIII-A was amplified by polymerase chain reaction from rFXIII-A construct pGF13A2, a kind gift from Dr C.S. Greenberg, Duke University Medical Center. 27 DNA sequencing confirmed the region of interest to be consistent with the FXIII-A subunit. The polymerase chain reaction product was digested with BglII and NotI, cloned into pGEX-6P-1, and transformed into DH5␣ E coli for screening. A recombinant FXIII-A double thrombin cleavage variant R37A/K513A was produced by introducing site-directed point mutations of wild-type rFXIII-A residues with the use of the QuickChangeII Site Directed Mutagenesis Kit carried out according to the manufacturers' instructions. DNA sequencing confirmed the mutations coding for R37A and K513A.
Expression and purification of recombinant proteins
All GST-tagged recombinant proteins (GST␣C fragments 1-9, GST␣ fragment 9 variants, GST-FXIII-A and GST-FXIII-A R37A/K513A) were expressed with the use of BL21-Gold E coli, following the method detailed in the supplemental material. GST fusion proteins were purified by GST-affinity chromatography with the use of an AKTAprime system, according to the recommended method by GE Healthcare. Details of the cell lysis, protein purification, and GST PreScission cleavage protocols used in this investigation can be found in supplemental Data.
Purification of Fibrogammin P FXIII-A 2 B 2 with the use of gel filtration chromatography
Fibrogammin P (CSL Behring) was used as a source of plasma FXIII-A 2 B 2 after isolation from other additives by gel filtration chromatography with the use of a Biocad sprint automated chromatography system (Perspective Biosystems) as detailed previously by Standeven et al. 28 For additional details see supplemental Data.
Purification of fibrinogen
Plasminogen-free fibrinogen from human plasma (Calbiochem) was prepared by ammonium sulfate precipitation to remove bound FXIII as described by Siebenlist et al. 25 For additional details see supplemental Data. The FXIII-free fibrinogen was screened by Western blotting and biotinlabeled pentylamine incorporation FXIII-A activity assay to confirm the removal of any contaminating FXIII. The fibrinogen concentration was determined at A 280 nm with the use of the extinction coefficient 1.51 for a solution of 1 mg/mL.
Biotin-labeled pentylamine incorporation FXIII-A activity assay
The cross-linking activity of purified FXIII-A 2 B 2 , rFXIII-A, and rFXIII-A R37A/K513A variant was determined with the use of a modified version of a 5-(biotinamido)pentylamine incorporation assay. 29 Modifications to the method can be found in supplemental Data.
Activation of rFXIII-A and FXIII-A 2 B 2
Recombinant FXIII-A and FXIII-A 2 B 2 were activated with the use of 5 U/mL human ␣-thrombin with 1.5mM calcium for 2 hours at 37°C, unless stated otherwise. The sample was centrifuged at 13 500 rpm for 5 minutes to remove precipitate, and the concentration was determined at A 280 nm with the use of the extinction coefficient 1.58 for a solution of 1 mg/mL. When removal of thrombin was necessary, biotinylated thrombin (Merck) was used at 5 U/mL for 2 hours at 37°C. Biotinylated thrombin was removed with the use of streptavidin agarose according to the manufacturer's protocol.
Surface plasmon resonance
In all cases SPR was performed with the use of a Biacore 3000 platform, and data were evaluated with BIAcore 3000 BIAevaluation 4.1 software (GE Healthcare).
Binding of rFXIII-A to fibrinogen ␣C region. With the use of SPR-calcium running buffer [20mM HEPES (N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid), 140mM NaCl, 1.5mM CaCl 2 , 0.05% (vol/vol) surfactant P20, pH 7.4] ϳ 2500 response units (RUs) of goat anti-GST antibody (GE Healthcare) was immobilized directly onto a CM5 sensor chip (flow cell 2) by amine coupling according to the manufacturer's instructions. A second flow cell (flow cell 1) was immobilized with the same antibody but was used as a blank reference cell. GST␣ fragment 1-9 (3.6M) was injected for 300 seconds at a flow rate of 20 L/min over flow cell (Fc) 2 to reach a capture level of ϳ 500 RU. rGST (100 g/mL; Sigma-Aldrich) was injected over Fc1 and 2 for 300 seconds at a flow rate of 20 L/min to block any remaining anti-GST binding sites. PreScission cleaved rFXIII-A was dialyzed for 16 hours at 4°C into SPR-calcium running buffer. Dialyzed rFXIII-A was thrombin activated and centrifuged, and the concentration was determined as described above. A 2-fold serial dilution of activated rFXIII-A (7.8-1000nM) was injected in ascending order for 60 seconds at a flow rate of 30 L/min over Fc1 and Fc2. Regeneration was achieved with buffer flow after stabilization for 300 seconds. Because of the rapid binding of activated rFXIII-A to the ␣C, it was not possible to perform kinetic analysis. The K d was therefore obtained with a predefined steady state affinity model with the use of a blank reference (Fc2-1, Fc4-3) and buffer subtracted data. This interaction was also performed in the reverse orientation to confirm the K d . With the use of SPR-calcium running buffer 5000 RU of activated rFXIII-A was directly immobilized onto a CM5 sensor chip as detailed above. ␣C fragments 1, 3, and 9 (cleaved from the GST tag) were dialyzed into SPR-calcium running buffer. A 2-fold serial dilution of 0.01-10M ␣C fragment was injected in ascending order for 60 seconds at a flow rate of 30 L/min over the immobilized activated rFXIII-A. Regeneration was achieved with buffer flow after stabilization for 300 seconds (n ϭ 3).
Binding of ␣ fragment 9 variants to activated rFXIII-A. ␣C fragment 9 variants were cleaved from the GST tag and dialyzed into SPR-calcium running buffer. A fixed concentration of 1M was injected over immobilized activated rFXIII-A for 60 seconds at a flow rate of 30 L/min. The binding response of each variant at 55 seconds, after buffer subtraction, was taken and plotted against the wild-type ␣ fragment 9 binding response for comparison (n ϭ 3).
Binding of FXIII-A 2 B 2 to fibrinogen ␣C region. Approximately 500 RU of GST␣ fragment 1 or GST␣ fragment 9 were captured on a CM5 sensor chip as described above. Nonactivated FXIII-A 2 B 2 and thrombincleaved FXIII-A 2 B 2 activated in the presence and absence of calcium were tested for binding to the captured GST␣ fragment 1 and 9. Two aliquots of purified FXIII-A 2 B 2 were dialyzed for 16 hours at 4°C into SPR-EDTA (ethylenediaminetetraacetic acid) buffer [20mM HEPES, 140mM NaCl, 5mM EDTA, 0.05% (vol/vol) surfactant P20, pH 7.4]. A third aliquot was dialyzed into SPR-calcium buffer pH 7.4. The FXIII-A 2 B 2 dialyzed into SPR-calcium buffer, and 1 of 2 FXIII-A 2 B 2 aliquots dialyzed into SPR-EDTA buffer were thrombin cleaved as described above. A 2-fold serial dilution (0.7-200nM) of nonactivated FXIII-A 2 B 2 or thrombin-cleaved FXIII-A 2 B 2 were injected for 60 seconds over the captured GST␣ fragment 1 or GST␣ fragment 9 at a flow rate of 30 L/min. Removal of bound FXIII-A 2 B 2 was achieved with the use of two 50-second pulses of 2M NaCl at a flow rate of 30 L/min. The surface was reequilibrated in running buffer for 300 seconds.
Binding of FXIII-A 2 B 2 to fibrinogen and fibrin.
Purified fibrinogen (100 RU) was immobilized directly onto a CM5 sensor chip (Fc2) by amine coupling according to the manufacturer's instructions. A blank reference surface (Fc1) was activated and deactivated as described above. The immobilized fibrinogen was converted to fibrin as previously described. 30 Purified FXIII-A 2 B 2 was dialyzed at 4°C for 16 hours into SPR-calcium running buffer and thrombin activated. A 2-fold serial dilution of thrombin and calcium-activated FXIII-A 2 B 2 (0.7-200nM) was injected over the immobilized fibrin at a flow rate of 30 L/min for 120 seconds. Removal of bound FXIII-A 2 B 2 was achieved with the use of two 40-second pulses of 5mM NaOH containing 100mM NaCl at a flow rate of 30 L/min. The surface was reequilibrated in running buffer for 300 seconds. Similar method was applied for analyses of the interactions between nonactivated FXIII-A 2 B 2 (in the absence of thrombin or calcium) and FXIII-A 2 B 2 cleaved by thrombin in the presence of EDTA (without calcium) with fibrinogen and fibrin. The SPR buffers contained EDTA or calcium to be consistent with the conditions used for the cleavage of FXIII by thrombin. Nonactivated or thrombin-only activated FXIII-A 2 B 2 was never exposed to calcium to prevent nonproteolytic activation thought to occur in the presence of calcium alone. Data were fitted to a bivalent analyte model because the 1:1 Langmuir binding model resulted in poor curve fitting ( 2 Ͻ 5 and 2 Ͼ 20, respectively). The bivalent analyte model was chosen to take into account the FXIII-A 2 and FXIII-B 2 dimers in the analyte FXIII-A 2 B 2 . However, the K d obtained for this interaction is an estimate only because fibrinogen is also a dimer that, when bound to FXIII-A 2 B 2 , would result in a complex multivalent interaction that would be difficult to fit to a kinetics model. All SPR investigations were tested for mass transfer with the use of a predefined Mass Transfer control wizard (BIAcore 3000 software Version 4.1). The results confirmed that in all cases the interaction rates observed were not limited by mass transfer (data not shown).
Competitive inhibition assay with the use of SPR
A CM5 sensor chip surface was used to capture GST␣ fragment 1 with the use of the same method as described above. GST-cleaved ␣C fragments 1-9 and rFXIII-A were dialyzed for 16 hours at 4°C into SPR-calcium running buffer. To determine the binding response from thrombin-activated rFXIII-A alone, 125nM was injected for 60 seconds over captured GST␣ fragment 1 at a flow rate of 30 L/min. The binding response was classified as 100% binding of activated rFXIII-A to the captured GST␣ fragment 1. Thrombin-activated rFXIII-A (125nM) was preincubated for 1 minute at 25°C with the cleaved ␣C fragments 1-9 at increasing molar concentrations of 12.5nM, 125nM, 1250nM, and 6250nM. The mix of activated rFXIII-A with ␣C fragment 1-9 was injected for 60 seconds at a flow rate of 30 L/min over the captured GST␣ fragment 1. The percentage binding response of the activated rFXIII-A binding to the captured GST␣ fragment 1 was plotted against the molar concentration of the ␣C fragment used in the preincubation with activated rFXIII-A. GST-cleaved ␣ fragment 9 was also used as a competitive inhibitor to ascertain whether the binding of activated FXIII-A 2 B 2 to the captured GST␣ fragment 1, and directly immobilized fibrin, could be inhibited. PreScission-cleaved ␣ fragment 9 was preincubated at increasing molar concentrations (0M, 0.012M, 0.125M, 1.25M, and 12.5M where 0M refers to activated FXIII-A 2 B 2 in the absence of ␣ fragment 9 competitor) for 60 seconds with 125nM thrombin-activated FXIII-A 2 B 2 in the presence of calcium. The sample was injected for 60 seconds at a flow rate of 30 L/min over captured GST␣ fragment 1 and immobilized fibrin. The binding response in response units was converted to percentage binding of FXIII-A 2 B 2 to the surface; captured GST␣ fragment 1 or immobilized fibrin was used for comparison (n ϭ 3).
Role of calcium in rFXIII-A activation and its effects on binding to the ␣C region 233-425 by SPR
Nonactivated rFXIII-A was dialyzed for 16 hours at 4°C into SPR-calcium running buffer, and a separate rFXIII-A aliquot was dialyzed into SPR-EDTA buffer. Both rFXIII-A aliquots were thrombin activated, and binding analysis was performed with the use of captured GST␣ fragment 1 as previously described, using SPR-calcium running buffer for the rFXIII-A sample activated in the presence of thrombin and calcium, and a second SPR-EDTA running buffer for rFXIII-A activated with thrombin only in the presence of EDTA. The rFXIII-A samples were injected for 60 seconds over the captured GST␣ fragment 1 at a flow rate of 30 L/min.
Effect of iodoacetamide inhibition of rFXIII-A on binding to ␣C
233-425 by SPR
rFXIII-A was dialyzed for 16 hours at 4°C into SPR-calcium running buffer. The rFXIII-A was thrombin activated and incubated with 50mM iodoacetamide (Sigma-Aldrich) for 15 minutes at 37°C. An aliquot of activated rFXIII-A in the absence of iodoacetamide was used for comparison. Before performing the binding study, 50mM iodoacetamide was injected for 60 seconds at a flow rate of 30 L/min over the captured GST␣ fragment 1. The iodoacetamide alone did not result in a binding response. Activated rFXIII-A (0.5M) in the presence and absence of 50mM iodoacetamide was injected at a flow rate of 30 L/min for 60 seconds over captured GST␣ fragment 1.
Results
Expression of recombinant ␣C truncations, rFXIII-A, and rFXIII-A-R37A/K513A
Recombinant GST␣ fragments 1-9 and ␣C fragments 1-9 cleaved from the GST tag were visualized with the use of sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE; Figure  1A -C) and exhibited major bands of the expected molecular mass as shown in Table 1 . SDS-PAGE analysis of thrombin-activated rFXIII-A clearly showed a decrease in molecular mass by ϳ 4 kDa, resulting from the N-terminal cleavage of the activation peptide by thrombin ( Figure 1D lanes 1-2) . This effect was not observed in the rFXIII-A R37A/K513A variant ( Figure 1D lanes 3-4) as predicted because R37 and K513 have been identified as thrombin cleavage sites. 9, 31 The FXIII-A pentylamine incorporation assay indicated that the wild-type rFXIII-A and FXIII-A 2 B 2 were active in contrast to variant rFXIII-A R37A/K513A which showed minimal crosslinking activity ( Figure 1E ).
Activated rFXIII-A subunit binds fibrinogen ␣C region 371-425
Binding of activated rFXIII-A was observed for GST␣ fragments 1, 2, 8, and 9 (␣233-425, ␣233-403, ␣289-425, and ␣371-425, respectively). Negligible binding was observed for ␣C fragments 3-7 (␣233-388, ␣233-375, ␣233-341, ␣233-290, and ␣233-265, respectively), which was too low to undertake formal analysis (data not shown). Figure 2 shows the binding of activated rFXIII-A to GST␣ fragment 1 and GST␣ fragment 9. Applying a steady state affinity model showed that GST␣ fragment 1 (␣233-425) bound to activated rFXIII-A with a K d of 2.35 Ϯ 0.09M, whereas GST␣ fragment 2 (␣233-403) bound with a K d of 2.64 Ϯ 1.21M. Competitive inhibition studies that used ␣C fragments 1 and 2 confirmed that the binding region for activated rFXIII-A was within ␣C 233-425. Complete inhibition of binding to captured GST␣ fragment 1 could not be achieved with the use of ␣ fragments 3-7, supporting the SPR data that the ␣C region 233-388 is not sufficient to mediate the interaction with activated rFXIII-A ( Figure 2C ). Rather, these results suggest the presence of essential determinants within the C-terminal portion of residues ␣389-403.
To further localize the ␣C binding region for activated rFXIII-A, amino-terminal truncations ␣ fragment 8 (␣289-425) and 9 (␣371-425) were used. Activated rFXIII-A bound GST␣ fragment 8 with a K d of 1.81 Ϯ 0.45M and GST␣ fragment 9 with a K d of 3.19 Ϯ 0.57M ( Figure 2B ; Table 1 ). Competitive inhibition studies that used ␣ fragments 8 and 9 showed complete inhibition of rFXIII-A binding to captured GST␣ fragment 1, comparable to the inhibition observed with the use of cleaved ␣ fragment 1 ( Figure 2D) .
To confirm the binding interaction, the experiment was performed in the reverse orientation by immobilizing activated rFXIII-A and injecting ␣C fragments 1, 9, and 3. The results showed that ␣C fragments 1 and 9 bound with a K d of 3.91 Ϯ 0.54M and 3.56 Ϯ 0.53M, respectively. Negligible binding was observed for ␣ fragment 3 (Figure 3 ). These data indicate that essential determinants of the fibrinogen ␣C binding region for activated rFXIII-A lie within ␣C residues 389-425 and are consistent with the localization of 389-403 deduced above. The localization is also in agreement with Procyk et al. 26 Molecular mass of recombinant fibrinogen ␣C fragments 1-9 in the presence and absence of the GST tag are also shown. With the use of a CM5 sensor chip anti-GST antibody capture approach on a BIAcore 3000 platform, a 2-fold serial dilution of activated rFXIII-A was injected for 60 seconds over captured GST␣ fragments 1-9. The data were evaluated with BIAcore 3000 BIAevaluation 4.1 software fitted to a predefined steady state affinity model with the use of blank reference and buffer subtracted data.
*Negligible binding was observed for GST␣ fragments 3, 4, 5, 6, and 7, which was too low to undertake formal analysis. (n ϭ 3).
Identification of a key amino acid residue involved in binding activated rFXIII-A
If the interaction between activated FXIII-A and the ␣C region is physiologically significant, it would be anticipated that key residues would be conserved between species. Alignment showed strong conservation of residues within 389-403 ( Figure 4A ). Site-directed mutagenesis of highly conserved amino acid residues within the ␣C region showed that a glutamic acid residue at position A␣396 is involved in the binding of activated rFXIII-A ( Figure 4B ), whereas substitution of 7 adjacent conserved residues was without effect. This suggests that FXIII-A is not binding to a linear binding site that is wholly contained within residues 389-403, but it is binding to an assembled determinant that also involves residues located between 371 and 389.
Nonactivated rFXIII-A does not bind fibrinogen ␣C region 233-425
SPR binding analysis showed that wild-type nonactivated rFXIII-A and the inactivate variant R37A/K513A did not bind to the captured GST␣ fragment 1 ( Figure 5A ). Furthermore, it was observed that the ␣C region 233-425 does not bind to rFXIII-A activated with thrombin only but also required the presence of calcium that induces a conformational change that exposes portions of FXIII-A that are not structurally exposed in the nonactivated form [13] [14] [15] ( Figure 5B ). Binding did not depend on catalytic activity because blocking the rFXIII-A active site Cys314 with iodoacetamide did not inhibit binding to the ␣C region 233-425, which occurred to the same degree as activated rFXIII-A in the absence of iodoacetamide ( Figure 5C ).
FXIII-A 2 B 2 binds with high affinity to fibrin(ogen) ␣C region 371-425
SPR was used to determine whether FXIII-A 2 B 2 bound to GST␣ fragment 1 (␣233-425) and GST␣ fragment 9 (␣371-425). With the use of a bivalent analyte model the SPR results showed that GST␣ fragment 1 (␣233-425) bound to nonactivated FXIII-A 2 B 2 (K d 1 ϭ 7.3 Ϯ 6.3nM), thrombin-cleaved FXIII-A 2 B 2 (no calcium; K d 1 ϭ 3.7 Ϯ 0.3nM), and thrombin-cleaved FXIII-A 2 B 2 activated in the presence of calcium (K d 1 ϭ 21.9 Ϯ 2.2nM; Table 2 ). In addition, the binding of the different activation states of FXIII-A 2 B 2 were further localized to fibrinogen ␣C 371-425 [nonactivated FXIII-A 2 B 2 : K d 1 ϭ 30.9 Ϯ 23nM; thrombin-cleaved FXIII-A 2 B 2 (no calcium): K d 1 ϭ 5.4 Ϯ 1.8nM; thrombin-cleaved FXIII-A 2 B 2 activated in the presence of calcium: K d 1 ϭ 7.3 Ϯ 1.8nM] ( Figure 6A ; Table 2 ). The SPR sensorgrams for the binding of FXIII-A 2 B 2 to GST␣ fragment 1 were identical to the those displayed for the binding of FXIII-A 2 B 2 to GST␣ fragment 9 and therefore are not shown. The various activation states of FXIII-A 2 B 2 were also tested for binding to full-length fibrinogen and fibrin. The results showed that both fibrinogen and fibrin bound to nonactivated FXIII-A 2 B 2 with a K d 1 of 11 Ϯ 4.7nM and 35.2 Ϯ 4nM, respectively, thrombincleaved FXIII-A 2 B 2 (no calcium) with a K d 1 of 2.9 Ϯ 2.1nM and 6.1 Ϯ 1nM, and thrombin-cleaved FXIII-A 2 B 2 activated in the presence of calcium with a K d 1 of 10.7 Ϯ 0.9nM and 14.5 Ϯ 3.1nM ( Figure 6B -C; Table 2 ).
␣ Fragment 9 (␣371-425), in the absence of the GST tag, was used as a competitive inhibitor to confirm the specificity of the interaction. The results showed that ␣ fragment 9 inhibited the binding of thrombin-cleaved FXIII-A 2 B 2 (activated in the presence of calcium) to the SPR-captured GST␣ fragment 1 and full-length fibrin (Figure 7 ). Furthermore, these results confirm that the interaction between the ␣ fragment 9 and activated FXIII-A 2 B 2 occurs in solution in addition to binding to an immobilized surface. 
Figure 2. Localization of the rFXIII-A-binding region on the ␣C of fibrinogen with the use of SPR.
With the use of a CM5 sensor chip anti-GST antibody capture approach, a serial dilution of activated rFXIII-A (7.8-1000nM) was injected for 60 seconds over captured GST␣ fragments 1-9 at a flow rate of 30 L/min. Sensorgrams shown are representative of triplicate data and display the double subtracted binding data for GST␣ fragments 1 (A) and 9 (B). Response units are plotted against time (n ϭ 3). (C) Competitive inhibition of activated rFXIII-A binding to captured GST␣ fragment 1. Thrombin-activated rFXIII-A (125nM) was preincubated for 5 minutes at 25°C with increasing molar concentrations (12.5nM, 125nM, 1250nM, 6250nM ) of GST-cleaved ␣ fragments 1-7. The mix of rFXIII-A/␣ fragment was injected for 60 seconds at a flow rate of 30 L/min over captured GST␣ fragment 1. The same experiment was performed with ␣ fragments 1, 8, and 9 (D). The binding response (RU) for each sample was converted to the percentage of binding of activated rFXIII-A to the captured GST␣ fragment 1 (y-axis) and plotted against the molar concentration of each ␣C fragment 1-7 (nM) added to the activated rFXIII-A (C) and ␣ fragments 1, 8, and 9 (D; n ϭ 3). Error bars show Ϯ 1 SD.
Discussion
Previous studies have shown the importance of the ␣C region for FXIII activation. The aim of this study was to characterize the interactions between FXIII-A and FXIII-A 2 B 2 with the fibrinogen ␣C region 233-425 that could contribute to this process. Using recombinant truncations of the fibrinogen ␣C region 233-425, we have identified a novel high-affinity interaction between FXIII-A 2 B 2 and fibrinogen ␣C region 371-425 which was evident both in the zymogen and after activation with thrombin and calcium. In addition, we have confirmed a previously described low-affinity interaction between activated FXIII-A and the ␣C region of fibrinogen, but we have extended the analysis to confirm the domain involved and to implicate a key residue, Glu396. The low-affinity interaction was dependent on calcium, which induces a conformational change in the ␤-barrel 1 and the ␤-sandwich domains of thrombin-cleaved FXIII-A. [13] [14] [15] In addition, calcium could mediate the interaction with Glu396. However, the lowaffinity interaction was independent of catalytic activity, showing that it did not arise from a transient covalent intermediate.
Low affinity and reversible binding of activated FXIII-A 2 to fibrinogen was reported by Procyk et al 26 with the use of antibodies specific for the ␣C region 389-402 and with the cyanogen bromide fragment Hi2-DSK (A␣241-476), suggesting that the location of the FXIII-A binding site was within ␣C region A␣389-402. 26 Our results obtained by mapping recombinant fragments implicate the same ␣C region and, in addition, present a key residue, Glu396, as being critical for binding activated FXIII-A. Furthermore, our data also imply that additional residues upstream (␣371-389) may contain secondary stabilizing sites that cannot function in the absence of Glu396, because it is unlikely that only one amino acid residue could make up the contact site for activated FXIII-A. The role of this interaction is currently undefined, but it is notable that the ␣C region 389-402 is close to the key ␣C glutamine residues (Gln366, Gln328, and Gln237) required for FXIII-A cross-linking that aid in clot formation and stabilization. Mutagenesis of the key interacting residue Glu396 in full-length fibrinogen will enable the putative role of the interaction in FXIII-A-mediated cross-linking to be assessed and will be of value in designing structural studies to identify the other residues comprising this binding site.
Our results also confirm high-affinity interactions between nonactivated and activated FXIII-A 2 B 2 and (1) a recombinant ␣C fragment of fibrinogen and (2) the ␣C region on fibrin. The tetrameric nature of the SPR analyte FXIII-A 2 B 2 , together with the dimeric structure of the ligand fibrin(ogen), which is thought to adopt a conformation similar to that of soluble fibrinogen when immobilized, 32 has the potential to result in a complex multivalent 36 of fibrinogen ␣C region 371-425 in 7 species to identify conserved residues for site-directed mutagenesis within the activated rFXIII-A binding region of ␣389-403. Amino acid residues highlighted in bold are highly conserved. (B) Displays the binding of each ␣ fragment 9 variant to activated rFXIII-A by SPR. Each ␣ fragment 9 variant (1M) was injected for 60 seconds over immobilized activated rFXIII-A at a flow rate of 30 L/min. The SPR response at 55 seconds was plotted for each of the variants and compared with wild-type (WT) ␣ fragment 9 (n ϭ 3). Error bars show Ϯ 1 SD.
Figure 5. Characterization of the interaction between rFXIII-A and ␣C region 233-425 by SPR. (A)
Comparison of activated wild-type rFXIII-A (red), with nonactivated wild-type (green), and rFXIII-A double thrombin cleavage mutant R37A/K513A (blue) binding to captured GST ␣ fragment 1. Both wild-type rFXIII-A and R37A/K513A variant were treated with thrombin (5 U/mL) and calcium (1.5mM) for 2 hours at 37°C. Activated wild-type rFXIII-A, R37A/K513A variant and wild-type nonactivated rFXIII-A (1M) were injected for 60 seconds at a flow rate of 30 L/min over captured GST␣ fragment 1. (B) The effect of calcium during rFXIII-A activation on binding to captured GST␣ fragment 1. rFXIII-A (1M), activated with 1.5mM calcium and 5 U/mL thrombin (red), and rFXIII-A (1M) activated with 5 U/mL thrombin in the presence of 5mM EDTA (blue) were injected for 60 seconds at a flow rate of 30 L/min over captured GST␣ fragment 1 for comparison. (C) The effect of 50mM iodoacetamide on rFXIII-A binding to captured GST␣ fragment 1. Wild-type activated rFXIII-A (0.5M) was preincubated with (blue) or without (red) 50mM iodoacetamide for 15 minutes at 37°C and injected for 60 seconds at a flow rate of 30 L/min over captured GST␣ fragment 1 for comparison. Sensorgrams shown in panels A, B, and C are representative of one experiment from triplicate runs (n ϭ 3). The binding response was observed with reference subtracted data. Response units are plotted against time in seconds.
interaction. However, SPR data are consistent with K d 1 dissociation constants in the range of 35nM. These values are in line with the K d (10nM) deduced by Greenberg and Shuman 19 for the binding of nonactivated plasma FXIII-A 2 B 2 to full-length fibrinogen, in this case monitoring the interaction on the surface of latex beads. Interactions between FXIII-A 2 B 2 and FXIII-A 2 with fibrin(ogen) have also been shown by immunoblotting, 24 clot binding assays, 21 and enzyme-linked immunoabsorbent assay. 20, 33 Greenberg et al have suggested that FXIII may circulate in plasma bound to the fibrinogen molecule, allowing the nonactivated FXIII to be present for cross-linking activity when required. 19 Interestingly, in our investigation all forms of FXIII bound similarly to the ␣C region, Data were evaluated with BIAcore 3000 BIAevaluation 4.1 software fitted to a bivalent analyte model with the use of blank reference and buffer subtracted data. The bivalent analyte model; A ϩ B 7 AB1: AB1 ϩ B 7 AB2, where A is the analyte and B is the ligand, results in 2 sets of rate constants; association (ka1/ka2), dissociation (kd1/kd2), and equilibrium dissociation constant (Kd1/Kd2). Kd1 (AB1) is clearly stronger than Kd2 (AB2) and is therefore the primary interaction considered in this study. The low-affinity second interaction (AB2 ͓Kd2͔) is less relevant than AB1, because it can only occur after AB1 formation and is generally thought of as a stabilizing interaction, supporting the formation of AB1. For each rate constant the average and SD of triplicate experiments are shown. * 2 Ͻ 5 for all analysis shown. Regeneration of binding was achieved with two 50-second injections of 2M NaCl for captured GST ␣ fragment 9 binding the FXIII-A 2B2 activation variants, and two 40-second injections of 5mM NaOH containing 100mM NaCl at a flow rate of 30 L/min for interactions between fibrin(ogen) and the FXIII-A2B2 activation variants (n ϭ 3). The SPR sensorgrams for the binding of FXIII-A 2B2 to GST␣ fragment 1 were indistinguishable from the binding to GST␣ fragment 9; therefore, they are not shown. All sensorgrams shown are representative of one experiment from triplicate runs (n ϭ 3).
suggesting that this region contributes to binding of FXIII to circulating fibrinogen, supporting the hypothesis proposed by Greenberg et al. However, Siebenlist et al 25 have proposed that circulating FXIII-A 2 B 2 binds preferentially to a subset of fibrinogen molecules that contain an extended ␥ chain as a result of alternative splicing of the ␥ chain mRNA and which comprise ϳ 10% of fibrinogen ␥ chains in the plasma. Fractionation of fibrinogen by anion exchange chromatography into pools enriched or depleted in ␥Ј chains have shown preferential association of FXIII-A 2 B 2 with the enriched pool. 25 However, it is notable that Gersh and Lord 34 have reported that fibrinogen of ␥/␥, ␥/␥Ј, and ␥Ј/␥Ј composition all bind FXIII-A 2 B 2 with a K d of 41nM, within the same order of magnitude as determined for the interaction between fibrinogen ␥/␥Ј and fibrin ␥/␥Ј with FXIII-A 2 B 2 (K d , 11nM and 35nM, respectively) observed in this investigation. The existence of an interaction between FXIII-A 2 B 2 and the ␣C region of fibrinogen is predicted by work from Credo et al 22 which reported that the presence of fibrinogen accelerates activation of FXIII, and more specifically the ␣C residues 242-424 enhanced the activation of FXIII to almost the same degree as full-length fibrinogen. 23 For this enhancement to occur an interaction between FXIII-A 2 B 2 and the ␣C regions of fibrinogen must take place at an early stage of clot formation. Our results show (1) that the ␣C region 371-425 binds with similar affinity to FXIII-A 2 B 2 to that displayed by full-length fibrinogen and (2) that the ␣C fragment 371-425 inhibited FXIII-A 2 B 2 binding to fibrin. We were not able to unequivocally demonstrate FXIII-A 2 B 2 binding to the ␣C region on full-length fibrinogen, as opposed to fibrin or the recombinant ␣C fragment. In this context, probably the best interpretation of currently available data are that ␥Ј chain binding is important to promote a carrier protein function for FXIII-A 2 B 2 and that the ␣C region:FXIII-A 2 B 2 interactions may have an important separate role during fibrin formation which may be to enhance FXIII activation. However, further functional studies of ␣C region:FXIII-A 2 B 2 interactions will need to be carried out to confirm this hypothesis.
In FXIII-A 2 B 2 , sushi domains 1-9 of FXIII-B mostly cover FXIII-A, 35 making it probable that binding of the nonactivated FXIII-A 2 B 2 to the fibrinogen ␣C region takes place by the B subunit. In ongoing studies, we have confirmed that the ␣C region binds to the B subunit (K.A.S., P.J.G., unpublished data, 2009). Thrombin, in the absence of calcium, cleaves the activation peptide from the amino-terminus of FXIII-A but does not dissociate the complex, 9 so that the interaction between fibrin and FXIII-A 2 B 2 might be expected to be maintained. Accordingly, in our hands thrombin cleavage of FXIII-A 2 B 2 did not affect FXIII-A 2 B 2 binding to the ␣C region 371-425. Finally, thrombin, in the presence of calcium, both cleaves the activation peptide from the amino-terminus of FXIII-A and causes dissociation of the FXIII-A 2 B 2 complex. We observed that the binding interaction was preserved, showing that it did not depend on the presence of both chains. We assume that FXIII-B may remain in complex with fibrinogen through a relatively tight interaction with a slow dissociation rate constant while activated FXIII-A is released. The relatively weak interaction of liberated FXIII-A with the ␣C is consistent with the need for the enzyme to be mobile to perform its cross-linking functions.
The results of this study localize the binding of FXIII-A 2 B 2 to a high-affinity interaction site on the ␣C region 371-425, in addition to a low-affinity ␣C binding site that involves key amino acid residue Glu396 for activated FXIII-A. Activated rFXIII-A binding is dependent on the conformational change induced by calcium and is independent of catalytic activity. These results support the view that interactions fundamental to FXIII-A 2 B 2 activation for ␣C cross-linking, fibrin formation, and stabilization are taking place in this region. Further studies are required to evaluate the effect of these interactions on thrombus formation in health and disease. ␣ fragment 9 (␣371-425) . PreScission-cleaved ␣ fragment 9 was preincubated, at increasing molar concentrations (0M, 0.012M, 0.125M, 1.25M, and 12.5M where 0M refers to activated FXIII-A2B2 in the absence of any ␣ fragment 9 competitor) for 60 seconds with 125nM thrombin-activated FXIII-A2B2 in the presence of calcium. The sample was injected for 60 seconds at a flow rate of 30 L/min over captured GST␣ fragment 1 and immobilized fibrin. The binding response (RU) was converted to the percentage of binding of FXIII-A2B2 to captured GST␣ fragment 1 (f) or immobilized fibrin (ࡗ). Results are normalized to binding in the absence of the competitor (n ϭ 3).
